Detail akcie Biocryst Pharm online

Business Summary: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Financial Summary: BRIEF: For the six months ended 30 June 2024, BioCryst Pharmaceuticals Inc revenues increased 34% to $202.1M. Net loss decreased 63% to $48.1M. Revenues reflect Product sales increase from $68.2M to $198.6M, Collaborative and other research increase from $612K to $3.5M. Lower net loss reflects Loss on extinguishment of debt decrease from $29M (expense) to $0K, Research and development decrease of 16% to $84.1M (expense).